Associated Genetic Biomarkers
RAD23B status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RAD23B status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with RAD23B status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is RAD23B Expression .
Hdac inhibitor cxd101 is the most frequent therapy in trials with RAD23B as an inclusion criteria .
Significance of RAD23B in Diseases
Malignant Solid Tumor +
RAD23B is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains RAD23B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.